The prevalence, disease burden and prognosis of COPD in patients with cardiovascular diseases

Trial Identifier: D2287L00041
Sponsor: AstraZeneca
Start Date: November 2025
Primary Completion Date: October 2026
Study Completion Date: December 2026
Condition: Heart, Blood & Circulatory - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100029
CN Beijing, CN, 100191
CN Beijing, CN, 100037
CN Chengdu, CN, 610041
CN Chengdu, CN, 610021
CN Chongqing, CN, 400010
CN Dongguan, CN, 523009
CN foshan, CN, CN-528000
CN Guangzhou, CN, 510515
CN Guangzhou, CN, 510080
CN Guangzhou, CN, 510100
CN Haikou, CN, 570311
CN Hubei, CN, 434300
CN Jiujiang, CN, 332000
CN Kaiyuan, CN, 661600
CN kunming, CN, 650032
CN Leping, CN, 333300
CN Linhai, CN, 317000
CN Mianyang, CN, 621000
CN Nanchang, CN, 330006
CN Shanghai, CN, 201114
CN Shanghai, CN, 200072
CN Shantou, CN, 515041
CN Shenyang, CN, 110004
CN Shenzhen, CN, 518036
CN Shijiazhuang, CN, 50051
CN Suining, CN, 629000
CN Xian, CN, 710100
CN Xuzhou, CN, 221009
CN Yangzhou, CN, 225001
CN Zhengzhou, CN, 450000
CN Zunyi, CN, 563100